BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1BMRN - US09061G1013 - Common Stock
50.7 EUR
+0.74 (+1.48%)
1BMRN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. 1BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. 1BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make 1BMRN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year 1BMRN was profitable.
- 1BMRN had a positive operating cash flow in the past year.
- 1BMRN had positive earnings in 4 of the past 5 years.
- In the past 5 years 1BMRN always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 6.83%, 1BMRN belongs to the best of the industry, outperforming 81.93% of the companies in the same industry.
- 1BMRN's Return On Equity of 8.59% is fine compared to the rest of the industry. 1BMRN outperforms 79.52% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 7.69%, 1BMRN belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
- 1BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 12.74%.
- The 3 year average ROIC (3.73%) for 1BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- 1BMRN has a better Profit Margin (16.82%) than 83.13% of its industry peers.
- 1BMRN has a better Operating Margin (20.21%) than 84.34% of its industry peers.
- 1BMRN's Gross Margin of 81.32% is fine compared to the rest of the industry. 1BMRN outperforms 71.08% of its industry peers.
- 1BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), 1BMRN is destroying value.
- The number of shares outstanding for 1BMRN has been increased compared to 1 year ago.
- The number of shares outstanding for 1BMRN has been increased compared to 5 years ago.
- 1BMRN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.56 indicates that 1BMRN is not in any danger for bankruptcy at the moment.
- 1BMRN's Altman-Z score of 5.56 is amongst the best of the industry. 1BMRN outperforms 80.72% of its industry peers.
- The Debt to FCF ratio of 1BMRN is 0.72, which is an excellent value as it means it would take 1BMRN, only 0.72 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.72, 1BMRN belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
- 1BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
- 1BMRN's Debt to Equity ratio of 0.10 is fine compared to the rest of the industry. 1BMRN outperforms 62.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.56 |
ROIC/WACC0.93
WACC8.29%
2.3 Liquidity
- A Current Ratio of 4.83 indicates that 1BMRN has no problem at all paying its short term obligations.
- 1BMRN's Current ratio of 4.83 is amongst the best of the industry. 1BMRN outperforms 80.72% of its industry peers.
- A Quick Ratio of 3.10 indicates that 1BMRN has no problem at all paying its short term obligations.
- 1BMRN's Quick ratio of 3.10 is fine compared to the rest of the industry. 1BMRN outperforms 69.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 52.00% over the past year.
- Looking at the last year, 1BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
- Measured over the past years, 1BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- 1BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.19% yearly.
- 1BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 22.24, which indicates a rather expensive current valuation of 1BMRN.
- Based on the Price/Earnings ratio, 1BMRN is valued cheaply inside the industry as 81.93% of the companies are valued more expensively.
- 1BMRN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.54.
- A Price/Forward Earnings ratio of 13.10 indicates a correct valuation of 1BMRN.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 93.98% of the companies listed in the same industry.
- 1BMRN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.31, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.24 | ||
| Fwd PE | 13.1 |
4.2 Price Multiples
- 1BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BMRN is cheaper than 81.93% of the companies in the same industry.
- 92.77% of the companies in the same industry are more expensive than 1BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.73 | ||
| EV/EBITDA | 14.45 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of 1BMRN may justify a higher PE ratio.
- A more expensive valuation may be justified as 1BMRN's earnings are expected to grow with 35.49% in the coming years.
PEG (NY)0.62
PEG (5Y)N/A
EPS Next 2Y42.79%
EPS Next 3Y35.49%
5. Dividend
5.1 Amount
- 1BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIT:1BMRN (1/2/2026, 7:00:00 PM)
50.7
+0.74 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners97.82%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap9.74B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target67.13 (32.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-18.5%
PT rev (3m)-19.34%
EPS NQ rev (1m)6.49%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)-11.66%
EPS NY rev (3m)-14.9%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.24 | ||
| Fwd PE | 13.1 | ||
| P/S | 3.66 | ||
| P/FCF | 13.73 | ||
| P/OCF | 12.41 | ||
| P/B | 1.87 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | 14.45 |
EPS(TTM)2.28
EY4.5%
EPS(NY)3.87
Fwd EY7.63%
FCF(TTM)3.69
FCFY7.28%
OCF(TTM)4.09
OCFY8.06%
SpS13.83
BVpS27.08
TBVpS25.16
PEG (NY)0.62
PEG (5Y)N/A
Graham Number37.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.56 |
F-Score8
WACC8.29%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y35.7%
EPS Next 2Y42.79%
EPS Next 3Y35.49%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.48%
Revenue Next 2Y10.76%
Revenue Next 3Y10.23%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y41.21%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to 1BMRN.MI.
What is the valuation status for 1BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (1BMRN.MI). This can be considered as Undervalued.
What is the profitability of 1BMRN stock?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for 1BMRN stock?
The Price/Earnings (PE) ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 22.24 and the Price/Book (PB) ratio is 1.87.